CN113624969A - Atp合酶c亚基胶体金快速检测试剂的使用方法 - Google Patents
Atp合酶c亚基胶体金快速检测试剂的使用方法 Download PDFInfo
- Publication number
- CN113624969A CN113624969A CN202110976557.9A CN202110976557A CN113624969A CN 113624969 A CN113624969 A CN 113624969A CN 202110976557 A CN202110976557 A CN 202110976557A CN 113624969 A CN113624969 A CN 113624969A
- Authority
- CN
- China
- Prior art keywords
- csub
- colloidal gold
- mouse igg
- igg antibody
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 238000001514 detection method Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 10
- 101710125656 ATP synthase c subunit Proteins 0.000 title claims abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 8
- 230000009471 action Effects 0.000 claims abstract description 4
- 238000003908 quality control method Methods 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 3
- 238000002331 protein detection Methods 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 8
- 208000010125 myocardial infarction Diseases 0.000 abstract description 3
- 208000007814 Unstable Angina Diseases 0.000 abstract description 2
- 230000008859 change Effects 0.000 abstract description 2
- 238000013399 early diagnosis Methods 0.000 abstract description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nanotechnology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了ATP合酶C亚基（Csub）胶体金快速检测试剂的使用方法，将特异性抗Csub的小鼠IgG抗体以条带状固定在膜上，胶体金标记抗Csub小鼠IgG抗体吸附在结合垫上，当待检样本加到试纸条一端的加样孔后，通过毛细作用结合并推动结合垫上的胶体金标记抗Csub小鼠IgG抗体向前移动，当抗体移动至固定的抗体区域时，Csub与胶体金标记抗Csub小鼠IgG抗体的结合物又与锚定于膜上的抗体发生特异性结合而被聚集在检测带上，胶体金检测速度极快，十分钟就可以判断，早期诊断价值巨大尤其是早期以不稳定心绞痛为表现的患者，而其他方法可能在出现明显改变时心肌缺血已经较为严重乃至于发展到心肌梗死的程度，对于早期干预有重大意义，进一步降低了患者与医院的负担。
Description
技术领域
本发明属于缺血性心脏病检测技术领域，特别涉及ATP合酶C亚基胶体金快速检测试剂的使用方法。
背景技术
缺血性心脏病是全球公认的导致人群死亡的主要原因之一，得益于高速发展的医疗卫生保障系统，近些年来IHD相关的死亡人数呈现快速下滑的态势，但不可否认的是，日益加快的生活工作节奏，熬夜，暴饮暴食等一系列因素使得IHD逐渐呈现年轻化的趋势。
肌钙蛋白作为诊断心肌梗死的有效标记物，在临床上广受认可，但是其是在心肌细胞发生损伤乃至坏死之后才释放入血，对于早期心肌缺血诊断、进展评估以及早期干预等方面存在不足，即便可以通过ELISA试剂盒或者蛋白免疫印记等方法检测Csub含量，不过上述检测方法检测时间较长动辄数小时，对于需要快速诊断及治疗的心肌缺血并不适合。
发明内容
本发明的目的就在于为了解决上述问题而提供ATP合酶C亚基胶体金快速检测试剂的使用方法。
为了解决上述问题，本发明提供了一种技术方案：
将特异性抗Csub的小鼠IgG抗体以条带状固定在膜上，胶体金标记抗Csub小鼠IgG抗体吸附在结合垫上，当待检样本加到试纸条一端的加样孔后，通过毛细作用结合并推动结合垫上的胶体金标记抗Csub小鼠IgG抗体向前移动，当抗体移动至固定的抗体区域时，Csub与胶体金标记抗Csub小鼠IgG抗体的结合物又与锚定于膜上的抗体发生特异性结合而被聚集在检测带上，显出肉眼可观察到的目的蛋白检测条带，而未与Csub结合的胶体金标记抗Csub小鼠IgG抗体与山羊抗鼠IgG抗体结合，显现出质控条带，则判断为阳性结果，如样本中没有待检测物，则只显示质控条带，不显示目的条带，则判断为阴性结果。
本发明的有益效果：成本较低，如果能采用自动话批量检测成本会进一步降低，胶体金检测速度极快，十分钟即可判断，早期诊断价值巨大尤其是早期以不稳定心绞痛为表现的患者，而其他方法可能在出现明显改变时心肌缺血已经较为严重乃至于发展到心肌梗死的程度，对于早期干预有重大意义，进一步降低了患者与医院的负担。
具体实施方式：
将特异性抗Csub的小鼠IgG抗体以条带状固定在膜上，胶体金标记抗Csub小鼠IgG抗体吸附在结合垫上，当待检样本加到试纸条一端的加样孔后，通过毛细作用结合并推动结合垫上的胶体金标记抗Csub小鼠IgG抗体向前移动，当抗体移动至固定的抗体区域时，Csub与胶体金标记抗Csub小鼠IgG抗体的结合物又与锚定于膜上的抗体发生特异性结合而被聚集在检测带上，显出肉眼可观察到的目的蛋白检测条带，而未与Csub结合的胶体金标记抗Csub小鼠IgG抗体与山羊抗鼠IgG抗体结合，显现出质控条带，则判断为阳性结果，如样本中没有待检测物，则只显示质控条带，不显示目的条带，则判断为阴性结果。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点，本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内，本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (1)
1.ATP合酶C亚基胶体金快速检测试剂的使用方法：
将特异性抗Csub的小鼠IgG抗体以条带状固定在膜上，胶体金标记抗Csub小鼠IgG抗体吸附在结合垫上，当待检样本加到试纸条一端的加样孔后，通过毛细作用结合并推动结合垫上的胶体金标记抗Csub小鼠IgG抗体向前移动，当抗体移动至固定的抗体区域时，Csub与胶体金标记抗Csub小鼠IgG抗体的结合物又与锚定于膜上的抗体发生特异性结合而被聚集在检测带上，显出肉眼可观察到的目的蛋白检测条带，而未与Csub结合的胶体金标记抗Csub小鼠IgG抗体与山羊抗鼠IgG抗体结合，显现出质控条带，则判断为阳性结果，如样本中没有待检测物，则只显示质控条带，不显示目的条带，则判断为阴性结果。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110976557.9A CN113624969A (zh) | 2021-08-24 | 2021-08-24 | Atp合酶c亚基胶体金快速检测试剂的使用方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110976557.9A CN113624969A (zh) | 2021-08-24 | 2021-08-24 | Atp合酶c亚基胶体金快速检测试剂的使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113624969A true CN113624969A (zh) | 2021-11-09 |
Family
ID=78387544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110976557.9A Pending CN113624969A (zh) | 2021-08-24 | 2021-08-24 | Atp合酶c亚基胶体金快速检测试剂的使用方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113624969A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090203734A1 (en) * | 2008-01-04 | 2009-08-13 | The Regents Of The University Of Michigan | F1f0-atpase inhibitors and related methods |
| CN107290527A (zh) * | 2017-07-31 | 2017-10-24 | 南京医科大学第附属医院 | 用于检测乙酰胆碱酯酶的胶体金层析快速诊断试纸条及其制备方法 |
-
2021
- 2021-08-24 CN CN202110976557.9A patent/CN113624969A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090203734A1 (en) * | 2008-01-04 | 2009-08-13 | The Regents Of The University Of Michigan | F1f0-atpase inhibitors and related methods |
| CN107290527A (zh) * | 2017-07-31 | 2017-10-24 | 南京医科大学第附属医院 | 用于检测乙酰胆碱酯酶的胶体金层析快速诊断试纸条及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| JUNKO SAKATA等: "Development of a rapid and simple immunochromatographic assay to identify Vibrio parahaemolyticus", JOURNAL OF MICROBIOLOGICAL METHODS, vol. 116, pages 23 * |
| 孙莹莹等: "血清线粒体ATP合酶C亚基水平在脓毒症患者心功能状态及预后评估中的价值", 中华医学杂志, vol. 101, no. 27, pages 63 - 64 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11486884B2 (en) | Methods and kits for the diagnosis and risk stratification of patients with ischemia | |
| JP5754767B2 (ja) | Ｐｓａの分析方法、及び前記分析方法を用いた前立腺癌と前立腺肥大症との鑑別方法 | |
| Yip et al. | Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty | |
| Cavus et al. | Heart-type, fatty-acid binding protein can be a diagnostic marker in acute coronary syndromes. | |
| JP2013509565A (ja) | Ｐｓａの分析方法、及び前記分析方法を用いた前立腺癌と前立腺肥大症との鑑別方法 | |
| US20240168037A1 (en) | Method of prognosis | |
| WO2016085866A1 (en) | Biomarkers and assay to detect chronic graft versus host disease | |
| AU2007210000A1 (en) | Storage-stable cellular whole blood composition containing elevated amounts of D-dimer | |
| CN113341154A (zh) | 一种检测血栓或凝血相关疾病的生物标志物及其应用 | |
| JP2012530253A (ja) | ペルオキシレドキシン４の診断的使用 | |
| US6068985A (en) | In vitro test for Helicobacter pylori | |
| Pfluecke et al. | Mon2-monocytes and increased CD-11b expression before transcatheter aortic valve implantation are associated with earlier death | |
| Langer et al. | Heart-type fatty acid-binding protein and myocardial creatine kinase enable rapid risk stratification in normotensive patients with pulmonary embolism | |
| CN113624969A (zh) | Atp合酶c亚基胶体金快速检测试剂的使用方法 | |
| WO2018223832A1 (zh) | 血浆s100a12在st段抬高型心肌梗死早期诊断中的应用 | |
| US20030124616A1 (en) | Homocysteinylated transthyretin | |
| JP2911602B2 (ja) | 診断のための補助物としての酵素指標の測定 | |
| US20110045504A1 (en) | Prognostic Prediction Method for Acute Coronary Syndrome | |
| Kaplan et al. | Geriatric nutritional risk index is a predictor of recurrent percutaneous coronary intervention in patients with non-ST segment elevation myocardial infarction | |
| Bakal et al. | Relationship between D-dimer and systemic embolism in patients with infective endocarditis | |
| CN113447660A (zh) | 人脑胶质瘤诊断elisa试剂盒及脑脊液app的应用 | |
| CN103344768B (zh) | 缺血性心脏病检测试剂盒及其应用 | |
| US7138239B2 (en) | Method and reagent for testing for multiple organ failure in SIRS by cytochrome C measurement | |
| Sun et al. | Growth differentiation factor 15 and coronary collateral formation | |
| Kaur et al. | Clinical significance and effectiveness of various serum biomarkers in diagnosis of myocardial infarction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211109 |
|
| RJ01 | Rejection of invention patent application after publication |